Related Experiment Video
Updated: Jun 8, 2025

Control of Eating Behavior Using a Novel Feedback System
Published on: May 8, 2018
The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity
Maryam Deravi1, Chris Piszczatoski2, Bradley Phillips3
1Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, FL.
Abstract:
Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. A literature review from April 2019 to April 2024 included such terms as "retatrutide," "LY3437943," "overweight," and "obesity." Phase I proof-of-concept studies led to phase II trials showing up to 24% body weight reduction and nearly 20 cm waist circumference reduction. The most common adverse effects were gastrointestinal. Ongoing phase II and III studies aim to further evaluate the safety and efficacy of retatrutide as a novel triagonist for obesity treatment.
Related Concept Videos
Obesity
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Regulation of Metabolism
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Antidepressant Drugs: MAOIs and Other Agents

